Macrolide antibiotics for bronchiectasis.
CONCLUSIONS: Long-term macrolide therapy may reduce the frequency of exacerbations and improve quality of life, although supporting evidence is derived mainly from studies of azithromycin, rather than other macrolides, and predominantly among adults rather than children. However, macrolides should be used with caution, as limited data indicate an associated increase in microbial resistance. Macrolides are associated with increased risk of cardiovascular death and other serious adverse events in other populations, and available data cannot exclude a similar risk among patients with bronchiectasis.
PMID: 29543980 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Kelly C, Chalmers JD, Crossingham I, Relph N, Felix LM, Evans DJ, Milan SJ, Spencer S Tags: Cochrane Database Syst Rev Source Type: research
More News: Allergy & Immunology | Antibiotic Therapy | Aspergillosis | Azithromycin | Biaxin | Cardiology | Cardiovascular | Children | Clarithromycin | Cough | CT Scan | Cystic Fibrosis | Databases & Libraries | Erythromycin | Gastroenteritis | Gastroenterology | General Medicine | Heart | Pneumonia | Radiography | Respiratory Medicine | Sarcoidosis | Staphylococcus Aureus | Study | Zithromax